Biosimilars Market Products, Applications and Regulations Overview 2024-2025 & 2030: Patent Expirations Drive Expansion for Cost-Effective Biosimilars, Regulatory Approvals Accelerate Adoption
06 mars 2025 06h38 HE
|
Research and Markets
Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Biosimilars Market - Products, Applications and Regulations" report has been added to ResearchAndMarkets.com's offering. The global biosimilars...
$22.68 Bn Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033
12 févr. 2025 04h04 HE
|
Research and Markets
Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has been added to ...
Growth Trends in the Insulin Biosimilar Market, Forecast to 2034
05 déc. 2024 10h28 HE
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Insulin Biosimilar Market by Type of Insulin, by Mode of Administration, by Therapeutic Application, by Distribution Channel, and by Region" report has...
Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,. Pfizer, Novartis, Teva, Boehringer Ingelheim, Celltrion, Samsungbioepis, Amgen
14 nov. 2024 07h14 HE
|
Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel,...
Biosimilars Market Industry Report 2024 - Rising Demand for Biosimilars as a Cost-effective Alternative has Promoted the Need for Increased In-house Development and Outsourcing Operations
08 nov. 2024 04h37 HE
|
Research and Markets
Dublin, Nov. 08, 2024 (GLOBE NEWSWIRE) -- The "Biosimilars Market Industry Trends and Global Forecasts to 2035 - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution...
Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review 2024: Drug Code/INN, Patent/Expiry, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 09h59 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...
Adalimumab (Humira) Biosimilars Pipeline Review 2024: A Recombinant Human IgG1 mAb - Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 09h57 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Adalimumab (Humira) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 09h55 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic...
Ranibizumab (Lucentis) Biosimilars Pipeline Review: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 09h54 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ranibizumab (Lucentis) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information...
Ustekinumab (Stelara) Biosimilars Pipeline Review: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24 oct. 2024 09h53 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ustekinumab (Stelara) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic...